{"id":"NCT00866775","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs","officialTitle":"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2009-03-20","resultsPosted":"2016-02-04","lastUpdate":"2016-03-11"},"enrollment":193,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy With Simple or Complex Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"Eslicarbazepine acetate","otherNames":[]},{"type":"DRUG","name":"Eslicarbazepine acetate","otherNames":[]}],"arms":[{"label":"Eslicarbazepine 1600 mg QD","type":"EXPERIMENTAL"},{"label":"Eslicarbazepine 1200 mg QD","type":"EXPERIMENTAL"}],"summary":"This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.","primaryOutcome":{"measure":"Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method","timeFrame":"Week 3 to Week 18","effectByArm":[{"arm":"Eslicarbazepine 1200 mg QD","deltaMin":0.444,"sd":null},{"arm":"Eslicarbazepine 1600 mg QD","deltaMin":0.287,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":106,"countries":["United States","Canada"]},"refs":{"pmids":["25689448"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":65},"commonTop":["Dizziness","Headache","Fatigue","Somnolence","Nausea"]}}